PD-L1 as a biomarker in NSCLC: challenges and future directions
Posted: Thu Jul 26, 2018 1:26 pm
Predictive value of PD-L1 testing in NSCLC
PD-L1 in previously treated NSCLC patients
Among patients with previously treated NSCLC, anti-PD-1/PD-L1 agents have consistently demonstrated improvements in overall survival (OS) compared to chemotherapy (Table 1). The phase III CheckMate (CM) 017 and 057 studies evaluated the role of nivolumab 3 mg/kg every 2 weeks in previously treated squamous and non-squamous advanced NSCLC, respectively (2,6). Both studies demonstrated statistically significant improvements in OS: 9.2 months for nivolumab compared to 6.0 months for docetaxel in CM 017 (HR 0.59, P<0.001) and 12.2 months for nivolumab compared to 9.4 months for docetaxel in CM 057 (HR 0.73, P=0.002). PD-L1 expression was assessed using the Dako 28-8 assay, and there was no minimum PD-L1 expression level required for study entry or primary endpoint analysis.
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=9.82143
PD-L1 in previously treated NSCLC patients
Among patients with previously treated NSCLC, anti-PD-1/PD-L1 agents have consistently demonstrated improvements in overall survival (OS) compared to chemotherapy (Table 1). The phase III CheckMate (CM) 017 and 057 studies evaluated the role of nivolumab 3 mg/kg every 2 weeks in previously treated squamous and non-squamous advanced NSCLC, respectively (2,6). Both studies demonstrated statistically significant improvements in OS: 9.2 months for nivolumab compared to 6.0 months for docetaxel in CM 017 (HR 0.59, P<0.001) and 12.2 months for nivolumab compared to 9.4 months for docetaxel in CM 057 (HR 0.73, P=0.002). PD-L1 expression was assessed using the Dako 28-8 assay, and there was no minimum PD-L1 expression level required for study entry or primary endpoint analysis.
https://www.ncbi.nlm.nih.gov/pmc/articl ... po=9.82143